Patents by Inventor Ken Olaussen

Ken Olaussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
    Patent number: 9702875
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 11, 2017
    Assignee: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY
    Publication number: 20140170659
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY
    Publication number: 20140120543
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Application
    Filed: September 9, 2013
    Publication date: May 1, 2014
    Applicant: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF
    Publication number: 20130281313
    Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to the identification of human genes and expression products thereof which can be used to assess the prognosis of a cancer in a subject, to assess the sensitivity of a subject to a treatment of cancer, or monitor, in particular determine the efficacy, of such a treatment of cancer after a given period of time. Said human genes and expression products can further be used (i) in the prevention or treatment of cancer, in particular to determine or select the appropriate cancer treatment for a given subject and/or for a particular tumor, as well as (ii) for the screening of therapeutically active drugs.
    Type: Application
    Filed: September 1, 2011
    Publication date: October 24, 2013
    Applicant: INSTITUT GUSTAVE ROUSSY
    Inventors: Lorenzo Galluzzi, Annick Harel-Bellan, Guido Kroemer, Ken Olaussen, Jean-Charles Soria